None listed
Conditions
Brief summary
Approximately 511,000 Australians live with heart failure. with more than 73,000 people being diagnosed each year. Following a first hospital admission for heart failure, 75% of people are readmitted within one year, and 33% die during that period. A simple admission for heart failure costs $3,440, whereas more complex admissions cost around $7,260, resulting in $3.1 billion in health costs per year. These data highlight the need to keep people living well in the community and out of hospital. There is an urgent need for new models of person-centred care to support self-care of heart failure at home and in the community. Digital health can transform the quality and sustainability of health and care. Our multidisciplinary team has co-designed and developed an innovative digital program, . It uses sensing technology, combined with artificial intelligence (AI) for early detection of heart failure deterioration. It prompts action by end-users, thereby improving opportunity for early intervention, and reducing further deterioration and re-hospitalisation
Interventions
Participants will be provided with the SMART system (wearables and tablet) free of charge to use for the duration of the intervention (90-days). A researcher/technical support staff will be available to assist with set-up and provide technical support as required.
The SMART model of delivery will involve a heart failure nurse meeting the person living with heart failure (and their carer, if available) to develop a care plan, assess community support, identify gaps, and initiate SMART. They will
Participants will be provided with the SMART system (wearables and tablet) free of charge to use for the duration of the intervention (90-days). A researcher/technical support staff will be available to assist with set-up and provide technical support as required. The SMART model of delivery will involve a heart failure nurse meeting the person living with heart failure (and their carer, if available) to develop a care plan, assess community support, identify gaps, and initiate SMART. They will outline how to establish a program of home surveillance (e.g., review of symptoms, weight, and vital signs), respond to the system and initiate the care plan. With the help of SMART, participants will be requested to record daily measurements of weight and blood pressure, answer questions about their symptoms, and to act in response to any changes. The behavioural goal is adherence to prescribed self-care activities. Provided devices will be Withings Smart Watch, Withings Blood Pressure monitor, Withings Scales and a tablet. Participants will engage with these devices for approximately 15-20 minutes per day to record their weight, blood pressure, fluid intake, medications and any symptoms they may be experiencing. Data collected will be monitored by the Deakin study staff. Any adverse symptoms recorded will alert the Cardiology nurse via email who can then reach out to the participant to discuss. Care plan will be as prescribed by the participants cardiologist. This study is providing daily monitoring to improve adherence and outcomes.
Sponsors
Deakin University
Study design
Allocation
Randomised controlled trial
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adults (aged 18 years or more) with a documented clinical diagnosis of heart failure, access to the internet, and ability to read and understand English language (for informed consent purposes) will be eligible.
Exclusion criteria
People with severe symptoms (persistent New York Heart Association IV), MI or unstable angina following intervention by Percutaneous Coronary Intervention (PCI) (less than 30 days or Coronary Artery Bypass Grafting (CABG) less than 60 days, unrevascularised coronary artery disease (CAD) with Chronic Coronary Syndrome (CCS) class III and IV, patients referred to a cardiac transplant unit, and patients with palliative intent. Individuals living in a long-term care establishment (e.g., care home), are planning to be away from home for 4 or more weeks during the intervention; or have any other disorder of such severity that life expectancy is less than 12 months.
Outcome results
None listed